Mupirocin resistance

Clinical Infectious Diseases

Volumn 49, Issue 6, 2009, Pages 935-941

  Patel, Jean B ^a,b   Gorwitz, Rachel J ^a   Jernigan, John A ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b Malistop G 08 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; PSEUDOMONIC ACID; RIFAMPICIN;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL GENE; GENE MUTATION; HUMAN; ILES GENE; LABORATORY TEST; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MUPA GENE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; COLONY COUNT, MICROBIAL; CONJUGATION, GENETIC; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUPIROCIN; NUCLEAR PROTEINS; PLASMIDS; STAPHYLOCOCCAL INFECTIONS;

EID: 70049095819     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605495     Document Type: Review

References (66)

1. Wertheim HF, Melles DC, Vos MC, et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 2005;5:751-762
2. Eltringham I. Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 1997;35:1-8.
3. Udo EE, Jacob LE, Mafhew B. Genetic analysis of methicillin-resistant Staphylococcus aureus expressing high- and low-level mupirocin resistance. J Med Microbiol 2001; 50:909-915
4. Hodgson JE, Curnock SP, Dyke KG, Morris R, Sylvester DR, Gross MS. Molecular characterization of the gene encoding high-level mupirocin resistance in Staphylococcus aureus J2870. Antimicrob Agents Chemother 1994;38:1205-1208
5. Antonio M, McFerran N, Pallen MJ. Mutations affecting the Rossman Fold of isoIeucyl-tRNA synthetase are correlated with low-level mupirocin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 2002; 46:438-442 (Pubitemid 34087193)
6. Simor AE, Stuart TL, Louie L, et al. Mupirocin-resistant, methicillinresistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother 2007;51:3880-3886
7. Chaves F, Garcia-Martinez J, de Miguel S, Otero JR. Molecular characterization of resistance to mupirocin in methicillin-susceptible and -resistant isolates of Staphylococcus aureus from nasal samples. J Clin Microbiol 2004; 42:822-824
8. Ramsey MA, Bradley SF, Kauffman CA, Morton TM.. Identification of chromosomal location of mupA gene, encoding low-level mupirocin resistance in staphylococcal isolates. Antimicrob Agents Chemother 1996; 40:2820-2823
9. Driscoll DG, Young CL, Ochsner UA. Transient loss of high-level mupirocin resistance in Staphylococcus aureusdue to mupA polymorphism. Antimicrob Agents Chemother 2007;51:2247-2248
10. Rahman M, Noble WC, Cookson B. Transmissible mupirocin resistance in Staphylococcus aureus. Epidemiol Infect 1989; 102:261-270
11. Morton TM, Johnston JL, Patterson J, Archer GL. Characterization of a conjugative staphylococcal mupirocin resistance plasmid. Antimicrob Agents Chemother 1995;39:1272-1280
12. Needham C, Rahman M, Dyke KG, Noble WC. An investigation of plasmids from Staphylococcus aureus that mediate resistance to mupirocin and tetracycline. Microbiology 1994; 140(Pt 10):2577-2583
13. Perez-Roth E, Lopez-Aguilar C, Alcoba-Florez J, Mendez-Alvarez S. High-level mupirocin resistance within methicillin-resistant Staphylococcus aureus pandemic lineages. Antimicrob Agents Chemother 2006; 50: 3207-3211
14. Hurdle JG, O'Neill AJ, Mody L, Chopra I, Bradley SF. In vivo transfer of high-level mupirocin resistance from Staphylococcus epidermidis to methicillin-resistant Staphylococcus aureus associated with failure of mupirocin prophylaxis. J Antimicrob Chemother 2005; 56:1166-1168
15. Diep BA, Chambers HF, Graber CJ, et al. Emergence of multidrugresistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA 300 in men who have sex with men. Ann Intern Med 2008; 148:249-257
16. Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA 300 isolates collected at a Boston ambulatory health center. J Clin Microbiol 2007;45:1350-1352
17. McDougal LK, Fosheim G, Patel JB; Team ABCs. Emergence of resistance among USA 300 MRSA isolates causing invasive disease in the US [abstract Cl-166]. In: Program and abstracts of the 48th Annual ICAAC/IDSA 46th Annual Meeting (Washington, DC). 2008:103.
18. Finlay JE, Miller LA, Poupard JA. Interpretive criteria for testing susceptibility of staphylococci to mupirocin. Antimicrob Agents Chemother 1997;41:1137-1139 (Pubitemid 27194199)
19. Fuchs PC, Jones RN, Barry AL. Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic. J Clin Microbiol 1990;28:608-609
20. Palepou MF, Johnson AP, Cookson BD, Beattie H, Charlett A, Woodford N. Evaluation of disc diffusion and Etest for determining the susceptibility of Staphylococcus aureus to mupirocin. J Antimicrob Chemother 1998;42:577-583
21. de Oliveira NE, Cardozo AP, Marques Ede A, dos Santos KR, Giambiagi-deMarval M. Interpretive criteria to differentiate low- and highlevel mupirocin resistance in Staphylococcus aureus. J Med Microbiol 2007;56:937-939
22. Creagh S, Lucey B. Interpretive criteria for mupirocin susceptibility testing of Staphylococcus spp. using CLSI guidelines. Br J Biomed Sci 2007;64:1-5.
23. Andrews JM. BSAC standardized disc susceptibility testing method (version 5). J Antimicrob Chemother 2006;58:511-529 (Pubitemid 44288114)
24. Zhang K, Sparling J, Chow BL, et al. New quadriplex PCR assay for detection of methicillin and mupirocin resistance and simultaneous discrimination of Staphylococcus aureus from coagulase-negative staphylococci. J Clin Microbiol 2004;42:4947-4955
25. Clinical and Laboratory Standards Institute/NCCLS. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. CLSI document M100-S19. Wayne, PA: CLSI, 2009.
26. Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of Chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant Staphylococcus aureus colonization. Clin Infect Dis 2007;44:178-185 (Pubitemid 46079977)
27. Walker ES, Vasquez JE, Dula R, Bullock H, Sarubbi FA. Mupirodnresistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective? Infect Control Hosp Epidemiol 2003; 24:342-346
28. Harbarth S, Liassine N, Dharan S, Herrault P, Auckenfhaler R, Pittet D. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2000;31:1380-1385
29. Upton A, Lang S, Heffernan H. Mupirocin and Staphylococcus aureus: a recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother 2003;51:613-617
30. Ellis MW, Griffith ME, Dooley DP, et al. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin- resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother 2007; 51:3591-3598
31. Irish D, Eltringham I, Teall A, et al. Control of an outbreak of an epidemic methicillin-resistant Staphylococcus aureus also resistant to mupirocin. J Hosp Infect 1998;39:19-26.
32. Raz R, Miron D, Colodner R, Staler Z, Samara Z, Keness Y. A 1-year trial of nasal mupirocin in the prevention of recurrent staphylococcal nasal colonization and skin infection. Arch Intern Med 1996; 156: 1109-1112 (Pubitemid 26158068)
33. Vasquez JE, Walker ES, Franzus BW, Overbay BK, Reagan DR, Sarubbi FA. The epidemiology of mupirocin resistance among methicillin-resistant Staphylococcus aureus at a Veterans Affairs hospital. Infect Control Hosp Epidemiol 2000;21:459-464
34. Hudson IR. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: a review of recent experience. J Hosp Infect 1994;27:81-98.
35. Caierao J, Berquo L, Dias C, d'Azevedo PA. Decrease in the incidence of mupirocin resistance among methicillin-resistant Staphylococcus aureus in carriers from an intensive care unit. Am J Infect Control 2006; 34:6-9.
36. Petinaki E, Spiliopoulou I, Kontos F, et al. Clonal dissemination of mupirocin-resistant staphylococci in Greek hospitals. J Antimicrob Chemother 2004;53:105-108 (Pubitemid 38072191)
37. Walker ES, Levy F, Shorman M, David G, Abdalla J, Sarubbi FA. A decline in mupirocin resistance in methicillin-resistant Staphylococcus aureus accompanied administrative control of prescriptions. J Clin Microbiol 2004;42:2792-2795
38. Paule SM, Robicsek A, Thomson RB Jr, Kaul KL, Peterson LR. Three years of universal surveillance and decolonization: the effect on mupirocin resistance [abstract C2-1069]. In: Program and abstracts of the 48th Annual ICAAC/IDSA 46th Annual Meeting (Washington, DC). 2008:171.
39. Boelaert JR, De Smedt RA, De Baere YA, et al. The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Nephrol Dial Transplant 1989; 4: 278-281
40. Perez-Fontan M, Rosales M, Rodriguez-Carmona A, Falcon TG, Valdês F. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 2002;39:337-411
41. Annigeri R, Conly J, Vas S, et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21:554-559
42. Perl TM., Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002; 346:1871-1877
43. Fawley WN, Parnell P, Hall J, Wilcox MH. Surveillance for mupirocin resistance following introduction of routine perioperative prophylaxis with nasal mupirocin. J Hosp Infect 2006;62:327-332 (Pubitemid 43192324)
44. van Rijen MM, Bonten M, Wenzel RP, KIuytmans JA. Intranasal mupirocin for reduction of Staphylococcus aureus infections in surgical patients with nasal carriage: a systematic review. J Antimicrob Chemother 2008;61:254-261
45. Torvaldsen S, Roberts C, Riley TV. The continuing evolution of methicillin-resistant Staphylococcus aureus in Western Australia. Infect Control Hosp Epidemiol 1999;20:133-135
46. Wiese-Posselt M, Heuck D, Draeger A, et al. Successful termination of a furunculosis outbreak due to lukS-lukF-pasitive, methicillin-susceptible Staphylococcus aureus in a German village by stringent decolonization, 2002-2005. Clin Infect Dis 2007;44:e88-95.
47. Archibald LK, Shapiro J, Pass A, Rand K, Soufhwick F. Methicillinresistant Staphylococcus aureus infection in a college football team: risk factors outside the locker room and playing field. Infect Control Hosp Epidemiol 2008;29:450-453
48. Campbell KM, Vaughn AF, Russell KL, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus infections in an outbreak of disease among military trainees in San Diego, California, in 2002. J Clin Microbiol 2004;42:4050-4053
49. West SK, Plantenga MS, Strausbaugh LJ. Use of decolonization to prevent staphylococcal infections in various healthcare settings: results of an Emerging Infections Network survey. Infect Control Hosp Epidemiol 2007;28:1111-1113
50. Lally RT, Lanz E, Schrock CG. Rapid control of an outbreak of Staphylococcus aureus on a neonatal intensive care department using standard infection control practices and nasal mupirocin. Am J Infect Control 2004;32:44-47
51. Rashid A, Solomon LK, Lewis HG, Khan K. Outbreak of epidemic methicillin-resistant Staphylococcus aureus in a regional burns unit: management and implications. Burns 2006; 32:452-457
52. Weber S, Herwaldt LA, McNutt LA, et al. An outbreak of Staphylococcus aureus in a pediatric cardiothoracic surgery unit. Infect Control Hosp Epidemiol 2002;23:77-81.
53. Redhead RJ, Lamb YJ, Rowsell RB. The efficacy of calcium mupirocin in the eradication of nasal Staphylococcus aureus carriage. Br J Clin Pract 1991;45:252-254
54. van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev 2008 (4):CD006216.
55. Vivoni AM, Santos KR, de-Oliveira MP, et al. Mupirocin for controlling methicillin-resistant Staphylococcus aureus: lessons from a decade of use at a university hospital. Infect Control Hosp Epidemiol 2005; 26:662-667
56. Jones JC, Rogers TJ, Brookmeyer P, et al. Mupirocin resistance inpatients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 2007;45:541-547
57. Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D'Agata EM. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis 2003;37: 1629-1638
58. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med 2008; 168:1585-1591
59. Creech CB, Beekmann SE, Chen Y, Polgreen PM. Variability among pediatric infectious diseases specialists in the treatment and prevention of methicillin-resistant Staphylococcus aureus skin and soft-tissue infections. Pediatr Infect Dis J 2008; 27:270-272
60. Miller LG, Quan C, Shay A, et al. A prospective investigation of outcomes after hospital discharge for endemic, community-acquired methicillin-resistant and -susceptible Staphylococcus aureus skin infection. Clin Infect Dis 2007;44:483-492
61. Davis SL, Perri MB, Donabedian SM, et al. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection. J Clin Microbiol 2007;45:1705-1711
62. Szumowski JD, Cohen DE, Kanaya F, Mayer KH. Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic. Antimicrob Agents Chemother 2007;51:423-428
63. Engelman R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons practice guideline series: antibiotic prophylaxis in cardiac surgery. II. Antibiotic choice. Ann Thorac Surg 2007;83:1569-1576
64. Bode LGM, KIuytmans JW, Wertheim HFL, et al. A randomized trial of admission screening and decolonization of Staphylococcus aureus carriers to prevent nosocomial S. aureus infections [abstract K-1711]. In: Program and abstracts of the 48th Annual ICAAC/IDSA 46th Annual Meeting (Washington, DC). 2008:512.
65. Siegel JD, Rhinehart E, Jackson M., Chiarello L; the Healthcare Infection Control Practices Advisory Committee. Management of multidrugresistant organisms in healthcare settings. 2006. Available at: http:// www.cdc.gov/ncidod/dhqp/pdf/ar/MDROGuideline2006.pdf. Accessed 27 July 2009.
66. Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008; 148:409-418